Hydrocortisone

Modify Date: 2024-01-01 20:04:12

Hydrocortisone Structure
Hydrocortisone structure
 Common Name Hydrocortisone
CAS Number 50-23-7 Molecular Weight 362.460
Density 1.3±0.1 g/cm3 Boiling Point 566.5±50.0 °C at 760 mmHg
Molecular Formula C21H30O5 Melting Point 211-214 °C(lit.)
MSDS Chinese USA Flash Point 310.4±26.6 °C
Symbol GHS08
GHS08		 Signal Word Warning

 Use of Hydrocortisone


Hydrocortisone is a steroid hormone or glucocorticoid secreted by the adrenal cortex.

 Names

Name cortisol
Synonym More Synonyms

 Hydrocortisone Biological Activity

Description Hydrocortisone is a steroid hormone or glucocorticoid secreted by the adrenal cortex.
Related Catalog
Target

Human Endogenous Metabolite
In Vitro Hydrocortisone (50 nM) shows a dose-dependent down-regulation of GR transcript in hCMEC/D3 cells. Hydrocortisone supplementation of the serum-reduced cell differentiation medium leads to a significant increase in TER across the hCMEC/D3 monolayer[1]. Hydrocortisone-treated Dendritic cells (DCs) show a decreased expression of MHC II molecules, the costimulatory molecule CD86, and the DC-specific marker CD83, as well as a strongly reduced IL-12 secretion. Hydrocortisone-treated DCs inhibit production of IFN-γ but induce an increased release of IL-4 and no change in IL-5[2]. Hydrocortisone reduces postischemic oxidative stress, perfusion pressure, and transudate formation. Hydrocortisone inhibits postischemic shedding of syndecan-1, heparan sulfate, and hyaluronan as is release of histamine from resident mast cells[3].
Cell Assay Cells are plated on top of collagen IV-coated transwell chambers for six-well plates (24 mm diameter, membrane material: polyethylene terephthalate (PET), 0.4 μm pores, pore density 1.6×106 cm2) at densities of 2.5×104 cells cm2 per well. When they have reached confluence at day 5, the different experimental sets of cells are transferred to differentiation medium containing reduced amounts of FCS and treated with TNFα or hydrocortisone as indicated.
References

[1]. F?rster C, et al. Differential effects of hydrocortisone and TNFalpha on tight junction proteins in an in vitro model of the human blood-brain barrier. J Physiol. 2008 Apr 1;586(7):1937-49.

[2]. Bellinghausen I, et al. Inhibition of human allergic T-cell responses by IL-10-treated dendritic cells: differences from hydrocortisone-treated dendritic cells. J Allergy Clin Immunol. 2001 Aug;108(2):242-9.

[3]. Chappell D, et al. Hydrocortisone preserves the vascular barrier by protecting the endothelial glycocalyx. Anesthesiology. 2007 Nov;107(5):776-84.

 Chemical & Physical Properties

Density 1.3±0.1 g/cm3
Boiling Point 566.5±50.0 °C at 760 mmHg
Melting Point 211-214 °C(lit.)
Molecular Formula C21H30O5
Molecular Weight 362.460
Flash Point 310.4±26.6 °C
Exact Mass 362.209320
PSA 94.83000
LogP 1.43
Vapour Pressure 0.0±3.5 mmHg at 25°C
Index of Refraction 1.595

 Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
GM8925000
CHEMICAL NAME :
Cortisol
CAS REGISTRY NUMBER :
50-23-7
LAST UPDATED :
199801
DATA ITEMS CITED :
45
MOLECULAR FORMULA :
C21-H30-O5
MOLECULAR WEIGHT :
362.51
WISWESSER LINE NOTATION :
L E5 B666 OV MUTJ A1 CQ E1 FV1Q FQ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
150 mg/kg
TOXIC EFFECTS :
Biochemical - Metabolism (Intermediary) - effect on inflammation or mediation of inflammation
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
449 mg/kg
TOXIC EFFECTS :
Nutritional and Gross Metabolic - weight loss or decreased weight gain
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>500 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
175 mg/kg/85D-I
TOXIC EFFECTS :
Endocrine - changes in adrenal weight Nutritional and Gross Metabolic - weight loss or decreased weight gain
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
140 mg/kg/7D-I
TOXIC EFFECTS :
Endocrine - changes in thymus weight Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
62 mg/kg/11D-I
TOXIC EFFECTS :
Endocrine - other changes
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
210 mg/kg
SEX/DURATION :
female 14 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - uterus, cervix, vagina
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
80 mg/kg
SEX/DURATION :
female 14-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - biochemical and metabolic
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
50 mg/kg
SEX/DURATION :
female 18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - biochemical and metabolic
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
330 mg/kg
SEX/DURATION :
female 1-22 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - endocrine system Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
220 mg/kg
SEX/DURATION :
female 9-19 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - endocrine system Reproductive - Effects on Newborn - biochemical and metabolic
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
200 mg/kg
SEX/DURATION :
female 14-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
500 mg/kg
SEX/DURATION :
female 13 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
50 mg/kg
SEX/DURATION :
female 16-18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - other effects to embryo
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Parenteral
DOSE :
35 mg/kg
SEX/DURATION :
female 7 day(s) pre-mating
TOXIC EFFECTS :
Reproductive - Maternal Effects - uterus, cervix, vagina
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
10 mg/kg
SEX/DURATION :
female 11-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
DOSE :
400 mg/kg
SEX/DURATION :
female 11-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
400 mg/kg
SEX/DURATION :
female 11-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
156 mg/kg
SEX/DURATION :
female 11-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
200 mg/kg
SEX/DURATION :
female 12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
400 mg/kg
SEX/DURATION :
female 11-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
200 mg/kg
SEX/DURATION :
female 12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraplacental
DOSE :
4 mg/kg
SEX/DURATION :
female 11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - other developmental abnormalities
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
6 mg/kg
SEX/DURATION :
female 24-26 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - other neonatal measures or effects Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Ocular
DOSE :
2945 ug/kg
SEX/DURATION :
female 6-18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
12 mg/kg
SEX/DURATION :
female 16-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - homeostasis
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
150 mg/kg
SEX/DURATION :
female 12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
333 mg/kg
SEX/DURATION :
female 10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
400 mg/kg
SEX/DURATION :
female 11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
Unscheduled DNA synthesis
TYPE OF TEST :
DNA inhibition
TYPE OF TEST :
Cytogenetic analysis
TYPE OF TEST :
DNA inhibition

MUTATION DATA

TYPE OF TEST :
DNA inhibition
TEST SYSTEM :
Bird - chicken Embryo
DOSE/DURATION :
450 pmol/L
REFERENCE :
NATUAS Nature. (Nature Subscription Dept., POB 1018, Manasguan, NJ 08736) V.1- 1869- Volume(issue)/page/year: 257,804,1975 *** REVIEWS *** TOXICOLOGY REVIEW CLPTAT Clinical Pharmacology and Therapeutics (St. Louis). (C.V. Mosby Co., 11830 Westline Industrial Dr., St. Louis, MO 63146) V.1- 1960- Volume(issue)/page/year: 5,480,1964 TOXICOLOGY REVIEW ADVPA3 Advances in Pharmacology. (New York, NY) V.1-6, 1962-68. For publisher information, see AVPCAQ. Volume(issue)/page/year: 4,263,1966 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 80429 No. of Facilities: 1374 (estimated) No. of Industries: 12 No. of Occupations: 15 No. of Employees: 28935 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 80429 No. of Facilities: 1396 (estimated) No. of Industries: 7 No. of Occupations: 20 No. of Employees: 36900 (estimated) No. of Female Employees: 21576 (estimated)

 Safety Information

Symbol GHS08
GHS08
Signal Word Warning
Hazard Statements H361
Precautionary Statements P281
Personal Protective Equipment Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges
Hazard Codes Xn:Harmful
Risk Phrases R62;R63
Safety Phrases S36/37-S45
RIDADR 2811.0
WGK Germany 3
RTECS GM8925000
Hazard Class 6.1
HS Code 2937210000

 Synthetic Route

 Customs

HS Code 2937210000

 Articles1583

More Articles
Functional consequence of the MET-T1010I polymorphism in breast cancer.

Oncotarget 6(5) , 2604-14, (2015)

Major breast cancer predisposition genes, only account for approximately 30% of high-risk breast cancer families and only explain 15% of breast cancer familial relative risk. The HGF growth factor rec...
Cell-cell adhesions and cell contractility are upregulated upon desmosome disruption.

PLoS ONE 9(7) , e101824, (2014)

Desmosomes are perturbed in a number of disease states - including genetic disorders, autoimmune and bacterial diseases. Here, we report unexpected changes in other cell-cell adhesion structures upon ...
MYC is a critical target of FBXW7.

Oncotarget 6(5) , 3292-305, (2015)

MYC deregulation is a driver of many human cancers. Altering the balance of MYC protein levels at the level of transcription, protein stability, or turnover is sufficient to transform cells to a tumor...

 Synonyms

Medicort
11b,17,21-Trihydroxyprogesterone
17a-Hydroxycorticosterone
H-Cort
(11β)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
11β,17,21-Trihydroxyprogesterone
Cleiton
Hydrocortisone
MFCD00011654
(11β)-11,17,21-Trihydroxy-pregn-4-ene-3,20-dione
Hydroxycorticosterone
Hydrocort
Kendall's compound F
(11b)-11,17,21-trihydroxypregn-4-ene-3,20-dione
4-Pregnene-11b,17a,21-triol-3,20-dione
17-hydroxycorticosterone
Hydrocorticosterone
11,17,21-trihydroxy-pregn-4-ene-3,20-dione
Hytone
Alacort
Signef
(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one
Efcortelin
Hydroxycortisone
Hycort
pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11b)-
hidrocortisona
Zenoxone
hydrocortisonum
CCN 90306A
Pregn-4-ene-3,20-dione, 11β,17,21-trihydroxy-
HVB
Hydrocortal
wycort
Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11β)-
Optef
Hydroskin
Eye-Cort
EINECS 200-020-1
17α-Hydroxycorticosterone
11β,17α,21-Trihydroxypregn-4-ene-3,20-dione
Top Suppliers:I want be here

Get all suppliers and price by the below link:

Hydrocortisone suppliers

Price: $66/10mM*1mLinDMSO

Reference only. check more Hydrocortisone price

Related Compounds: More...
Hydrocortisone
60103-17-5
Hydrocortisone
74050-20-7
Hydrocortisone-d2
1257650-73-9
Hydrocortisone-d4
73565-87-4
Hydrocortisone-d3
115699-92-8
D1-Hydrocortisone
50-24-8
no-hydrocortisone
571186-50-0
Hydrocortisone 21-he
2203-97-6
hydrocortisone valerat
57524-89-7
Chemsrc provides Hydrocortisone(CAS#:50-23-7) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of Hydrocortisone are included as well.>> amp version: Hydrocortisone

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved